Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone

A technology of methylpiperazine and zopiclone, which is applied in the field of medicine, can solve problems such as lack of standards, potential safety hazards, and inability to evaluate the quality of medicines, achieving high accuracy, high equipment penetration rate, and good separation

Inactive Publication Date: 2021-10-26
JIANGSU TASLY DIYI PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, 4-methylpiperazine-1-carboxylic acid methyl ester, 4-methylpiperazine-1-carboxylic acid ethyl ester, 4-methylpiperazine-1-carboxylic acid ethyl ester, 4-methylpiperazine-1 -The inspection method for the residual content of isopropyl formate, the standard is missing, there are no relevant literature reports at home and abroad, it is impossible to evaluate the quality of the drug, and there are potential safety hazards

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone
  • Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone
  • Method for determining residual content of 4-methylpiperazine-1-formate genotoxic impurities in zopiclone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1~3

[0070] Blank solvent: Acetonitrile

[0071] Preparation of reference solution

[0072] Weigh 0.01024 g of methyl 4-methylpiperazine-1-carboxylate into a 10 mL brown volumetric flask, add diluent to dissolve and dilute to the mark to obtain methyl 4-methylpiperazine-1-carboxylate stock solution I.

[0073] Weigh 0.00998 g of ethyl 4-methylpiperazine-1-carboxylate into a 10 mL brown volumetric flask, add diluent to dissolve and dilute to the mark to obtain ethyl 4-methylpiperazine-1-carboxylate stock solution I.

[0074] Weigh 0.00995 g of isopropyl 4-methylpiperazine-1-carboxylate into a 10 mL brown volumetric flask, add diluent to dissolve and dilute to the mark to obtain isopropyl 4-methylpiperazine-1-carboxylate stock solution I.

[0075] Precisely pipette 125 μL of the above 4-methylpiperazine-1-carboxylic acid methyl ester stock solution Ⅰ, 4-methylpiperazine-1-carboxylic acid ethyl ester stock solution Ⅰ 125 μL, 4-methylpiperazine-1-carboxylic acid isopropyl ester 125 μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
recovery rateaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for determining the residual contents of 4-methyl piperazine-1-methyl formate, 4-methyl piperazine-1-ethyl formate and 4-methyl piperazine-1-isopropyl formate in zopiclone. The method comprises the following steps: preparing a contrast solution: precisely weighing a proper amount of methyl 4-methylpiperazine-1-formate, a proper amount of ethyl 4-methylpiperazine-1-formate and a proper amount of isopropyl 4-methylpiperazine-1-formate, putting the weighed materials into a volumetric flask, dissolving the weighed materials with acetonitrile, diluting the dissolved materials, and respectively preparing 125ng / mL limit concentration solutions; preparing a test sample solution: precisely weighing a proper amount of zopiclone test sample, placing the zopiclone test sample in a volumetric flask, dissolving and diluting the zopiclone test sample with acetonitrile, and preparing the zopiclone test sample into a 1mg / mL solution; and sample determination: respectively taking the test solution and the reference solution, directly injecting the test solution and the reference solution into a GCMS, recording a chromatogram, and calculating by peak areas according to an external standard method to obtain the contents of the 4-methylpiperazine-1-methyl formate, the 4-methylpiperazine-1-ethyl formate and the 4-methylpiperazine-1-isopropyl formate in the test solution.

Description

technical field [0001] The invention belongs to the field of medicine technology, relates to the field of medicine impurity detection, in particular to a method for determining the residual content of 4-methylpiperazine-1-carboxylate genotoxic impurities in zopiclone, and the determined genotoxic impurity is 4-formazine Methyl piperazine-1-carboxylate, ethyl 4-methylpiperazine-1-carboxylate, isopropyl 4-methylpiperazine-1-carboxylate. Background technique [0002] Zopiclone (Zopiclone, ZOP), the chemical name is 6-(5-chloro-2-pyridyl)-7-[(4-methylpiperazin-1-yl) carboxyoxy]-5,6-dihydro Pyrrolo[3,4-b]pyrazin-5-one belongs to pyrrole cyclic ketone compounds, as a new type of non-benzodiazepine sedative hypnotics that has been used clinically, it can be effectively used in the treatment of insomnia Short term treatment. Racemic zopiclone has been marketed by the French company Rhone-Poulenc Rorer under the trade names IMOVANE and AMOBAN in more than 80 countries including Eur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/86
CPCG01N30/02G01N30/06G01N30/8679G01N2030/047
Inventor 杨国英丁爱忠孔凯丽杨国军
Owner JIANGSU TASLY DIYI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products